Project Grant R15HL181720
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $588K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This Project Grant award of $234,000.00 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the University of Colorado-Denver to develop "hemostatic red blood cells" (T-RBCs) that can bind to collagen and fibrin to enhance clot formation and stability. The goal is to create a novel technology to address severe, non-compressible bleeding, which is a major cause of mortality worldwide, especially in low-resource settings. The...
- This Project Grant award from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) totaling $715,110.00 aims to develop and optimize a novel "nano-RBC" blood substitute prototype. The key products and services to be delivered include: The project will use computational studies, synthetic and biological experiments to design a "smart" oxygen-delivery biomaterial with physiological oxygen binding/dissociation properties,...
- This federal Project Grant award of $1,356,922.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of novel hydrogel-coated electrospun (HES) biomaterials for replacement heart valves. The key objectives are to: Identify optimal biomaterial and leaflet geometry characteristics to develop replacement heart valves with greater durability, resistance to thrombosis, and improved hemodynamics. This will leverage the...
- This federal Project Grant award of $110,635.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to characterize how red blood cell aggregation and membrane deformability affect endothelial cell injury and microvascular thrombosis in sepsis patients. The project will use microfluidics assays to analyze patient blood samples and apply machine learning to determine the impact of rheology on clinical outcomes. The research will also assess the...
- This $568,264 Project Grant (R41HL178144) was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to SAFI Biotherapeutics Inc., a pre-clinical blood cell therapy company based in Cambridge, MA. The goal of this Phase I STTR project is to develop a scalable bioprocess for manufacturing designer red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). These designer RBCs will serve as reagents to...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $693,423 to Baylor College of Medicine to develop and validate a novel microfluidic device capable of purifying platelets for pediatric and neonatal transfusions. The goal is to create a simple, disposable device that can effectively remove contaminants from platelet suspensions while preserving high-functioning platelets. The project will optimize the efficiency of...
- This Project Grant award of $375,306 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to advance personalized transfusion medicine by identifying optimal procedures to yield platelet products with maximum hemostatic capacity. The key products or services to be delivered include: Identifying the thiol redox status of cold-stored platelets compared to room temperature-stored platelets, and the specific redox switches associated with improved...
- This $702,534 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at Texas A&M Engineering Experiment Station (Tees) to develop an integrated super-resolution cardiac magnetic resonance imaging-deep learning (CMR-DL) technology. The goal is to isolate and quantify the contributions of passive and active mechanisms to impaired left ventricular relaxation, a key driver of left ventricular diastolic dysfunction...
- This Project Grant award of $392,660 from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) aims to investigate the role of red blood cells (RBCs) in regulating the inflammatory response during sepsis. The key research objectives are to: 1) establish the subcellular localization of Toll-like Receptor 7 (TLR7) in human RBCs and determine their RNA-sequestration capabilities during sepsis, 2) determine how RBC-expressed TLR7 delivers RNA to...
- This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) is providing $1,031,644 to support research on precision metering and autonomous separation of blood components for pre-clinical microsampling at the point-of-care. The primary awardee, Trustees of Tufts College, will develop functional patient-centric devices that can stabilize...